<DOC>
	<DOCNO>NCT02221375</DOCNO>
	<brief_summary>The objective study investigate safety , tolerability pharmacokinetics butylate hydroxytoluene ( BHT ) ( sub-study 1 ) administer via Respimat® Soft MistTM Inhaler B ( SMI B ) ; assess safety , tolerability pharmacokinetics multiple rise dos BI 54903 XX administer via Respimat® SMI B ( main study ) , compare systemic exposure single dose BI 54903 XX administer via Respimat® SMI B ( sub-study 2 ) single dose Alvesco® ( ciclesonide ) administer via HFA-134a propellant meter dose inhaler ( MDI ) .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Multiple Rising Doses Butylated Hydroxytoluene BI 54903 XX Via Respimat® Soft MistTM Inhaler B Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Butylated Hydroxytoluene</mesh_term>
	<criteria>Healthy male base upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) clinical laboratory test Age &gt; = 21 &lt; = 50 year BMI &gt; = 18.5 &lt; = 29.9 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 h ) within least one month le 10 halflives respective drug prior administration trial Use drug could reasonably influence result trial within 10 day prior administration trial ( base knowledge time protocol preparation ) Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipe per day ) Inability refrain smoke trial day Alcohol abuse ( 60 g per day ) Drug abuse Blood donation ( &gt; 100 mL within 4 week prior administration trial ) Excessive physical activity ( within 1 week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site Bacterial viral infection lung , include active latent tuberculosis</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>